Answers are grounded in this paper and cite their sources.
Overview reveals inebilizumab's effects on IgG4-related disease, suggesting improved treatment options.
This article provides an overview of advances in treatment strategies for IgG4-RD, shedding light upon the characteristics of inebilizumab and results of the clinical trials. Various targeted therapies under the development are expected to overcome limitations in safety and efficacy of glucocorticoids and to reduce risk of organ damage and fibrosis.
No takes yet. Share an insight, caveat, or question.
Yoshiya Tanaka (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: